Novartis AG bears the distinction of being the first to market with a cell therapy, the CAR-T Kymriah (tisagenlecleucel), which won US Food and Drug Administration approval in August 2017 for acute lymphoblastic leukemia (ALL) in children, followed by diffuse large B-cell lymphoma (DLBCL) for adults the next year. But since then, it has fallen behind the second CAR-T to win approval, Gilead Sciences, Inc.’s Yescarta (axicabtagene ciloleucel). Now, Novartis is hoping to regain a leading role in the cell therapy space with new data in multiple myeloma at the American Society of Clinical Oncology meeting.
Both companies presented data for their CAR-Ts at ASCO in early June, including Gilead presentations on Yescarta and its sister product Tecartus (brexucabtagene autoleucel) – which, like Kymriah, target CD19 – and a presentation of data by Novartis on PHE885, its BCMA-directed CAR-T
Key Takeaways
-
Novartis presented early efficacy data for PHE885, its BCMA-directed CAR-T for multiple myeloma that uses T-Charge technology for faster manufacturing.
-
Its marketed CAR-T, Kymriah, was the first to win FDA approval in 2017, but it has since fallen behind in terms of sales, which declined in 2022 relative to 2021
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
